326 related articles for article (PubMed ID: 30204909)
1. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
Dubash S; Marianayagam T; Tinazzi I; Al-Araimi T; Pagnoux C; Weizman AV; Richette P; Tran Minh ML; Allez M; Singh A; Ciccia F; Hamlin J; Tan AL; Marzo-Ortega H; McGonagle D
Rheumatology (Oxford); 2019 Jun; 58(6):963-968. PubMed ID: 30204909
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients.
Ruscio MD; Tinazzi I; Variola A; Geccherle A; Marchetta A; McGonagle D
Rheumatology (Oxford); 2021 Dec; 60(12):5809-5813. PubMed ID: 33580246
[TBL] [Abstract][Full Text] [Related]
3. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
4. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
5. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.
Varkas G; Thevissen K; De Brabanter G; Van Praet L; Czul-Gurdian F; Cypers H; De Kock J; Carron P; De Vos M; Hindryckx P; Arts J; Vanneuville I; Schoenaers P; Claerhout B; Abreu M; Van den Bosch F; Elewaut D
Ann Rheum Dis; 2017 May; 76(5):878-881. PubMed ID: 27899374
[TBL] [Abstract][Full Text] [Related]
6. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.
Turkcapar N; Toruner M; Soykan I; Aydintug OT; Cetinkaya H; Duzgun N; Ozden A; Duman M
Rheumatol Int; 2006 May; 26(7):663-8. PubMed ID: 16136311
[TBL] [Abstract][Full Text] [Related]
8. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
9. Introducing vedolizumab to clinical practice: who, when, and how?
Bryant RV; Sandborn WJ; Travis SP
J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
[TBL] [Abstract][Full Text] [Related]
10. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
11. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
13. Seronegative spondyloarthropathy-associated inflammatory bowel disease.
Wang CR; Tsai HW
World J Gastroenterol; 2023 Jan; 29(3):450-468. PubMed ID: 36688014
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
15. Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Bridgewood C; Watad A; Cuthbert RJ; McGonagle D
Curr Opin Rheumatol; 2018 Sep; 30(5):526-532. PubMed ID: 29889692
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
17. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
18. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.
Guo D; Jiang K; Hong J; Zhang M; Shi Y; Zhou B
Int J Colorectal Dis; 2021 Oct; 36(10):2081-2092. PubMed ID: 34467414
[TBL] [Abstract][Full Text] [Related]
19. Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.
Subramaniam K; Tymms K; Shadbolt B; Pavli P
Intern Med J; 2015 Nov; 45(11):1154-60. PubMed ID: 26337851
[TBL] [Abstract][Full Text] [Related]
20. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
